Remestemcel-L

Summary

Remestemcel-L (CHEMBL2108046) is a phase-3 clinical-stage cell; indicated across 5 conditions including crohn disease and graft versus host disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 5 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108046
Name	Remestemcel-L
Type	Cell
Max phase	3

Also known as: JR-0301, Prochymal, Remestemcel, Remestemcel-l, REMESTEMCEL-L

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Crohn disease	3	MONDO:0005011	EFO:0000384
graft versus host disease	3	MONDO:0013730	EFO:0004599
acute respiratory distress syndrome	3	MONDO:0006502	EFO:1000637
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
ulcerative colitis	1	MONDO:0005101	EFO:0000729

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
Not specified	4
PHASE3	3
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02336230	PHASE3	COMPLETED	A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
NCT02652130	PHASE3	COMPLETED	Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
NCT04371393	PHASE3	TERMINATED	MSCs in COVID-19 ARDS
NCT00284986	PHASE2	COMPLETED	Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants
NCT04543994	PHASE1/PHASE2	TERMINATED	Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
NCT04548583	PHASE1/PHASE2	TERMINATED	Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn’s Colitis
NCT00759018	Not specified	NO_LONGER_AVAILABLE	Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
NCT01510431	Not specified	NO_LONGER_AVAILABLE	Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn’s Disease
NCT04366830	Not specified	NO_LONGER_AVAILABLE	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
NCT04456439	Not specified	NO_LONGER_AVAILABLE	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).